“Increased Demand for Personalized Treatment”
The tolterodine market is experiencing growth due to the rising prevalence of overactive bladder (OAB) and urinary incontinence, particularly among the aging population. Tolterodine, an antimuscarinic agent, is widely used for controlling symptoms of OAB. Recent innovations in drug formulations, such as extended-release versions, have improved patient adherence and minimized side effects. A significant trend in the market is the shift towards generic versions of tolterodine, making the drug more affordable and accessible. The market is also seeing increased demand for personalized treatment options as healthcare systems focus on tailored care. As awareness of OAB grows and treatment options improve, the tolterodine market is expected to expand, with new advancements further enhancing its therapeutic potential.
